Dresdner Kleinwort Wasserstein Begins Coverage of Genomic Sector | GenomeWeb

NEW YORK, Sept. 26 - Dresdner Kleinwort Wasserstein has begun covering a handful of “special niche” genomic and proteomic companies, the financial company said on Wednesday.

The coverage, which will be led by analyst Charles C. Duncan, will include Celgene, CuraGen, Exelixis, Human Genome Sciences, Millennium Pharmaceuticals, Myriad Genetics, Tularik, and Vertex Pharmaceuticals. These all were rated a “Buy,” the company said in a statement. Two more companies, Celera Genomics and Sangamo BioSciences, were rated an “Add.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."